Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 3
2021 3
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study.
Lamarque C, Segaux L, Bachellier P, Buchard B, Chermak F, Conti F, Decaens T, Dharancy S, Di Martino V, Dumortier J, Francoz-Caudron C, Gugenheim J, Hardwigsen J, Muscari F, Radenne S, Salamé E, Uguen T, Ursic-Bedoya J, Antoine C, Deshayes A, Jacquelinet C, Natella PA, Leroy V, Cherqui D, Oubaya N, Duvoux C. Lamarque C, et al. Among authors: buchard b. J Hepatol. 2024 Mar 21:S0168-8278(24)00202-2. doi: 10.1016/j.jhep.2024.03.019. Online ahead of print. J Hepatol. 2024. PMID: 38521171 Free article.
Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort).
Carrieri P, Bourlière M, Di Beo V, Lusivika-Nzinga C, Ramier C, Antwerpes S, Protopopescu C, Lacombe JM, Pol S, Fontaine H, Mourad A, Carrat F, Duracinsky M, Marcellin F; ANRS/AFEF HEPATHER Study Group. Carrieri P, et al. Qual Life Res. 2023 Dec;32(12):3427-3438. doi: 10.1007/s11136-023-03496-w. Epub 2023 Aug 16. Qual Life Res. 2023. PMID: 37587323
Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort.
Barré T, Carrat F, Ramier C, Fontaine H, Di Beo V, Bureau M, Dorival C, Larrey D, Delarocque-Astagneau E, Mathurin P, Marcellin F, Petrov-Sanchez V, Cagnot C, Carrieri P, Pol S, Protopopescu C; ANRS/AFEF Hepather study group. Barré T, et al. J Cannabis Res. 2022 Jun 11;4(1):31. doi: 10.1186/s42238-022-00138-9. J Cannabis Res. 2022. PMID: 35690798 Free PMC article.
Morbid obesity increases death and dropout from the liver transplantation waiting list: A prospective cohort study.
Delacôte C, Favre M, El Amrani M, Ningarhari M, Lemaitre E, Ntandja-Wandji LC, Bauvin P, Boleslawski E, Millet G, Truant S, Mathurin P, Louvet A, Canva V, Lebuffe G, Pruvot FR, Dharancy S, Lassailly G; French ABM study group. Delacôte C, et al. United European Gastroenterol J. 2022 May;10(4):396-408. doi: 10.1002/ueg2.12226. Epub 2022 Apr 26. United European Gastroenterol J. 2022. PMID: 35470965 Free PMC article.
Noninvasive biomarkers of non-alcoholic fatty liver disease in patients with metabolic syndrome: insights from the RESOLVE Study.
Ennequin G, Buchard B, Pereira B, Bonjean L, Courteix D, Lesourd B, Chapier R, Obert P, Vinet A, Walther G, Zak M, Bagheri R, Ugbolue CU, Abergel A, Dutheil F, Thivel D. Ennequin G, et al. Among authors: buchard b. Minerva Gastroenterol (Torino). 2023 Dec;69(4):494-503. doi: 10.23736/S2724-5985.22.03139-4. Epub 2022 Feb 10. Minerva Gastroenterol (Torino). 2023. PMID: 35144365
Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort).
Barré T, Pol S, Ramier C, Di Beo V, Carrat F, Bureau M, Bourlière M, Dorival C, Serfaty L, Asselah T, Boursier J, Marcellin F, Carrieri P, Fontaine H, Protopopescu C; ANRS/AFEF Hepather Study Group. Barré T, et al. Cannabis Cannabinoid Res. 2022 Oct;7(5):677-689. doi: 10.1089/can.2021.0094. Epub 2021 Oct 13. Cannabis Cannabinoid Res. 2022. PMID: 34648718 Free PMC article.
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
Abergel A, Asselah T, Mallat A, Chanteranne B, Faure F, Larrey D, Gournay J, Loustaud-Ratti V, Di Martino V, Fouchard-Hubert I, Pol S, Bailly F, Samuel D, Tran A, Dodel M, Andant N, Lamblin G, Muti L, Reymond M, Teilhet C, Pereira B, Buchard B. Abergel A, et al. Among authors: buchard b. Liver Int. 2020 Aug;40(8):1853-1859. doi: 10.1111/liv.14502. Epub 2020 Jun 1. Liver Int. 2020. PMID: 32383275 Clinical Trial.
13 results